Luca Giulio Cossa
Overview
Explore the profile of Luca Giulio Cossa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefano E, Cossa L, Castro F, De Luca E, Vergaro V, My G, et al.
Bioinorg Chem Appl
. 2023 Sep;
2023:5564624.
PMID: 37727647
Pancreatic cancer is one of the most lethal malignancies with an increasing incidence and a high mortality rate, due to its rapid progression, invasiveness, and resistance to anticancer therapies. In...
2.
Muscella A, Resta L, Cossa L, Marsigliante S
Biomolecules
. 2023 Aug;
13(8).
PMID: 37627246
This study aimed to evaluate AT1-R expression in normal and cancerous human kidneys, how these expressions are modified, and AT1-R functionality. AT-1R mRNA expression, determined by real-time PCR, was detected...
3.
Muscella A, Cossa L, Vetrugno C, Marsigliante S
Mol Cell Endocrinol
. 2020 Mar;
507:110771.
PMID: 32114020
Local mediator prostaglandins and bradykinin are involved in inflammation and pain. We explored bradykinin effects on prostaglandin E2 (PGE2) release from fibroblasts derived from human skeletal muscular biopsies. Bradykinin induced...
4.
Muscella A, Vetrugno C, Cossa L, Marsigliante S
J Neurochem
. 2019 Nov;
153(4):525-538.
PMID: 31729763
Following peripheral nerve injury, remnant Schwann cells adopt a migratory phenotype and remodel the extracellular matrix allowing axonal regrowth. Although much evidence has demonstrated that TGF-β1 promotes glioma cell motility...
5.
Antonaci G, Cossa L, Muscella A, Vetrugno C, De Pascali S, Fanizzi F, et al.
Biomolecules
. 2019 Mar;
9(3).
PMID: 30845773
We have demonstrated the cytotoxic effects of [Pt(,'-acac)(γ-acac)(dimethyl sulfide (DMS))] on various immortalized cell lines, in primary cultures, and in murine xenograft models in vivo. Recently, we also showed that...
6.
Muscella A, Cossa L, Vetrugno C, Antonaci G, Marsigliante S
J Cell Physiol
. 2018 Aug;
234(4):4409-4417.
PMID: 30144378
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor in which cisplatin therapy is commonly used, although its effectiveness is limited. It follows that research efforts dedicated to identify promising...
7.
Muscella A, Cossa L, Vetrugno C, Antonaci G, Marsigliante S
Ann N Y Acad Sci
. 2018 Jul;
1431(1):72-84.
PMID: 29984433
Although an association between cancer progression and matrix metalloproteinase (MMP) 2 and MPP9 expression has been known, the expression, nuclear localization, and physiologically controlled activation of these two MMPs have...
8.
Muscella A, Vetrugno C, Cossa L, Antonaci G, Barca A, De Pascali S, et al.
PLoS One
. 2018 Feb;
13(2):e0193030.
PMID: 29432478
[This corrects the article DOI: 10.1371/journal.pone.0181114.].
9.
Muscella A, Vetrugno C, Cossa L, Antonaci G, Barca A, De Pascali S, et al.
PLoS One
. 2017 Jul;
12(7):e0181114.
PMID: 28704484
Mesothelioma cancer cells have epithelioid or sarcomatoid morphology. The worst prognosis is associated with sarcomatoid phenotype and resistance to therapy is affected by cells heterogeneity. We recently showed that in...
10.
Muscella A, Vetrugno C, Cossa L, Antonaci G, De Nuccio F, De Pascali S, et al.
PLoS One
. 2016 Nov;
11(11):e0165154.
PMID: 27806086
Malignant pleural mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy. There is an urgent need for effective therapy inasmuch as resistance, intrinsic and acquired, to conventional therapies is...